A Case of Moderate Hidradenitis Suppurativa and Psoriasis Treated with Secukinumab

Abstract

Hidradenitis suppurativa (HS) is a disorder of the apocrine gland causing a chronic, recurrent and painful inflammation. It is a disabilitating condition and, though many therapeutic options are available, the response is often ineffective in most cases and patients can present many recurrences with physical and psychological sequelae. Recent data had shown increased interleukin (IL)-17 serum levels in patients with HS. Psoriasis is a chronic immune-mediated inflammatory disorder and new evidences have shown the role of Th17 cells in its pathogenesis and the therapeutic efficacy of anti-IL-17 antibodies. We present a case of a patient suffering from psoriasis and HS successfully treated with anti-IL-17 antibodies for both conditions. This is the first case report of HS treated with secukinumab.

One drug and two diseases: A case of multidrug‐resistant hidradenitis suppurativa and psoriasis treated with apremilast

“…The coexistence of HS and psoriasis in the same patient is rare and choosing the right therapy to treat both the conditions can be challenging (Giuseppe et al, ).…”

Secukinumab and hidradenitis suppurativa: Friends or foes?

“…Therefore, IL-17 pathway may play a key role in HS pathogenesis. Currently, 4 case reports described a significant improvement of lesion activity and inflammation with secukinumab in HS patients 4, 5, 6, 7. Furthermore, secukinumab is now in phase I trial for HS treatment.…”

Severe hidradenitis suppurativa successfully treated with secukinumab

“…To the best of our knowledge, there have only been four cases of secukinumab treatment administered to HS patients reported in the literature. [5][6][7][8] Moreover, one open-label study with nine patients…”